Skip to content

How Glaucoma Eye Drops Affect Eye Surface Health And Comfort

Prevalence And Patterns of Ocular Surface Disease Among Glaucoma Patients On Topical Medications - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/098126
Enrollment
98
Registered
2025-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H409- Unspecified glaucoma

Interventions

Intervention1: Nil: Nil

Sponsors

Datta Meghe Institute Of Higher Education And Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: DIAGNOSED CASES OF GLAUCOMA (PRIMARY OPEN ANGLE, ANGLE CLOSURE, PSEUDOEXFOLIATION, PIGMENTARY GLAUCOMA) ON TOPICAL ANTIGLAUCOMA MEDICATIONS FOR MORE THAN 6 MONTHS WILLINGNESS TO PROVIDE WRITTEN INFORMED CONSENT. SUBJECTS NOT USING ANY TOPICAL OCULAR MEDICATIONS

Exclusion criteria

Exclusion criteria: USE OF TOPICAL STEROIDS OR LUBRICANTS HISTORY OF OCULAR SURGERY SECONDARY GLAUCOMA (E.G., UVEITIC, LENS-INDUCED) CONTACT LENS USERS KNOWN SYSTEMIC DISEASES AFFECTING TEAR FILM (E.G., SJOGRENS SYNDROME)

Design outcomes

Primary

MeasureTime frame
TO IDENTIFY CLINICAL AND DEMOGRAPHIC RISK FACTORS (E.G., AGE, COMORBIDITIES, POLYPHARMACY) ASSOCIATED WITH OCULAR SURFACE DISEASES IN GLAUCOMA PATIENTS.Timepoint: 1ST DAY & 15TH DAY

Secondary

MeasureTime frame
TO DETERMINE THE PREVALENCE AND SEVERITY OF OSD IN GLAUCOMA PATIENTS (EG- USING OSDI (OCULAR SURFACE DISEASES INDEX), TBUT(TEAR BREAKUP TIME), SCHIRMER S TEST, AND LISSAMINE GREEN STAINING). TO COMPARE THESE FINDINGS WITH HEALTHY CONTROLS. TO ASSESS THE CORRELATION BETWEEN OSD (OCULAR SURFACE DISEASES) SEVERITY AND NUMBER/DURATION OF ANTIGLAUCOMA MEDICATIONS. TO ASSESS THE IMPACT OF PRESERVATIVE-CONTAINING VERSUS PRESERVATIVE-FREE FORMULATIONS ON OCULAR SURFACE PARAMETERS. TO EXPLORE TREATMENT PATTERNS AND GAPS IN THE CURRENT MANAGEMENT OF OSD IN GLAUCOMATimepoint: 1ST & 15TH DAY

Countries

India

Contacts

Public ContactDr Shashank Banait

Datta Meghe Institute Of Higher Education And Research

shashankbanait@yahoo.co.in9822226124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026